Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Belantamab + Belantamab mafodotin-blmf + Dexamethasone + Lenalidomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Belantamab | GSK2857914|GSK-2857914|GSK 2857914 | TNFRSF17 Antibody 22 | Belantamab is a monoclonal antibody targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (PMID: 34253590). | |
| Belantamab mafodotin-blmf | Blenrep | anti-BCMA ADC GSK2857916|J6M0-mcMMAF|GSK2857916 | TNFRSF17 Antibody 22 | Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262). Blenrep (belantamab mafodotin-blmf) in combination with Velcade (bortezomib), and Dexamethasone is FDA-approved for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy (FDA.gov). |
| Dexamethasone | Adexone | Desametasone | ||
| Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05714839 | Phase I | Belantamab Belantamab + Belantamab mafodotin-blmf + Dexamethasone + Lenalidomide Belantamab mafodotin-blmf | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20) | Recruiting | USA | POL | GBR | BRA | AUS | ARG | 3 |